TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-centered Care Transitions in Heart Failure: A Pragmatic Cluster
Brief Summary: Heart failure (HF) is the most common cause of hospitalization in older adults. The month after hospital discharge represents a vulnerable period, when patients are at increased risk of death and readmission to hospital. Research has shown that certain discharge-planning services can reduce death and readmissions, but these have not been widely implemented. In this study, we will group evidence-informed discharge-planning services into 'Patient-centered Care Transitions in HF' (PACT-HF), a model of care that will prepare patients for their transition from hospital to home. Through PACT-HF, patients will benefit from a comprehensive assessment of their health care needs, learn to recognize and manage symptoms of HF, and receive the information and follow-up care needed to optimize their health. We will introduce PACT-HF to 10 Ontario hospitals over a number of time periods using a stepped wedge cluster trial design. We will compare the outcomes (hierarchically ordered) of patients in hospitals with PACT-HF to those in hospitals without PACT-HF. We anticipate that patients hospitalized at the sites with PACT-HF will have fewer readmissions, emergency visits, and deaths after discharge; report a better quality of life; and feel more prepared for discharge. We also anticipate that overall, PACT-HF will reduce health system costs.


Options:
A: Arm Label: SHHE Peridischarge intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SHHE Peridischarge Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SHHE Peridischarge Intervention; Assigned to Arm(s): SHHE Peridischarge intervention
B: Arm Label: MI + IVR; Type: EXPERIMENTAL; Interventions: Behavioral: MI + IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MI + IVR; Assigned to Arm(s): MI + IVR
C: Arm Label: Discharge planning services; Type: ACTIVE_COMPARATOR; Interventions: Other: PACT-HF Model | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PACT-HF Model; Assigned to Arm(s): Discharge planning services
D: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Link2Care; Type: EXPERIMENTAL; Interventions: Other: Link2Care | Intervention Type: OTHER; Name: Link2Care; Assigned to Arm(s): Link2Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi Center, Study to Evaluate the Safety and Efficacy of the VasQ External Support Device for Brachiocephalic Arteriovenous Fistula
Brief Summary: This study is a prospective, multi center, randomized, controlled study of the VasQ in arteriovenous fistulas. The VasQ constraints and directs the geometrical parameters of the fistula as well as the vascular diameter and gradient in the vicinity of the AV shunt. These geometrical constraints direct flow and influence hemodynamics, and hence minimize turbulence and promote laminar flow. The device is designed to improve short term maturation and long term patency of the fistula. The VasQ is a permanent implant intended for use as a subcutaneous arteriovenous conduit support for vascular access.


Options:
A: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: PRT-201; Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: GTN patch; Type: EXPERIMENTAL; Interventions: Drug: GTN patch | Arm Label: Placebo patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo comparator | Intervention Type: DRUG; Name: GTN patch; Assigned to Arm(s): GTN patch | Intervention Type: DRUG; Name: placebo comparator; Assigned to Arm(s): Placebo patch
D: Arm Label: AV fistula with VasQ; Type: EXPERIMENTAL; Interventions: Device: VasQ | Arm Label: AV fistula; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: VasQ; Assigned to Arm(s): AV fistula with VasQ

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Vitamin D Supplementation Prevent Food Allergy in Infants? the VITALITY Trial
Brief Summary: We report that Australia has the highest prevalence of Immunoglobulin(Ig)E-mediated food allergy in the world, with 10% of infants having challenge-proven food allergy in Melbourne. There has been a 5-fold increase in hospital admissions for life-threatening anaphylaxis. These changes are most pronounced in children less than 5 years, suggesting a causal role for early life determinants. We have primary data to inform hypotheses for the rise in food allergy, which appears to result from potentially modifiable factors related to the modern lifestyle, particularly Vitamin D insufficiency (VDI). We propose an intervention study to assess if infant Vitamin D supplementation during the first year of life significantly decreases the risk of early-onset food allergy and other allergic disease at 12 months (part 1) and 6 years of age (part 2). Australia is ideally placed to answer this important question since, unlike the USA, Canada and Europe, there are no population recommendations for routine infant supplementation with Vitamin D and we are one of the few developed countries that do not supplement the food chain supply with Vitamin D.


Options:
A: Arm Label: High-dose vitamin D; Type: EXPERIMENTAL; Interventions: Drug: High-dose vitamin D 3 | Arm Label: Conventional-dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional-Dose Vitamin D 3 | Intervention Type: DRUG; Name: High-dose vitamin D 3; Assigned to Arm(s): High-dose vitamin D | Intervention Type: DRUG; Name: Conventional-Dose Vitamin D 3; Assigned to Arm(s): Conventional-dose vitamin D
B: Arm Label: vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): vitamin D | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: choecalciferol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol; Assigned to Arm(s): choecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Sustained; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Diet-Limited; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Diet-Limited | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Sustained

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Vitamin D Supplementation Prevent Food Allergy in Infants? the VITALITY Trial
Brief Summary: We report that Australia has the highest prevalence of Immunoglobulin(Ig)E-mediated food allergy in the world, with 10% of infants having challenge-proven food allergy in Melbourne. There has been a 5-fold increase in hospital admissions for life-threatening anaphylaxis. These changes are most pronounced in children less than 5 years, suggesting a causal role for early life determinants. We have primary data to inform hypotheses for the rise in food allergy, which appears to result from potentially modifiable factors related to the modern lifestyle, particularly Vitamin D insufficiency (VDI). We propose an intervention study to assess if infant Vitamin D supplementation during the first year of life significantly decreases the risk of early-onset food allergy and other allergic disease at 12 months (part 1) and 6 years of age (part 2). Australia is ideally placed to answer this important question since, unlike the USA, Canada and Europe, there are no population recommendations for routine infant supplementation with Vitamin D and we are one of the few developed countries that do not supplement the food chain supply with Vitamin D.


Options:
A: Arm Label: Atopic dermatitis patients: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral vitamin D | Arm Label: Atopic dermatitis patients: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: oral vitamin D; Assigned to Arm(s): Atopic dermatitis patients: Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Atopic dermatitis patients: Placebo
B: Arm Label: Vitamin D3 100,000 IU; Type: EXPERIMENTAL; Interventions: Drug: Experimental: Vitamin D3 100,000 IU | Arm Label: Vitamin D3 12,000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Comparator: Vitamin D3 12,000 IU | Intervention Type: DRUG; Name: Experimental: Vitamin D3 100,000 IU; Assigned to Arm(s): Vitamin D3 100,000 IU | Intervention Type: DRUG; Name: Active Comparator: Vitamin D3 12,000 IU; Assigned to Arm(s): Vitamin D3 12,000 IU
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin D3 placebo | Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3 placebo; Assigned to Arm(s): placebo
D: Arm Label: vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): vitamin D | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of the Effectiveness of a Nurse-led Self-efficacy Enhancing Stroke Self-management Program for Community-dwelling Stroke Survivors
Brief Summary: The aim of this study is to examine the effectiveness of a nurse-led self-efficacy enhancing stroke self-management program on recovery of community-dwelling stroke survivors.


Options:
A: Arm Label: Stroke self-management program; Type: EXPERIMENTAL; Interventions: Behavioral: Stroke self-management program, Behavioral: Usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Stroke self-management program; Assigned to Arm(s): Stroke self-management program | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Stroke self-management program, Usual care
B: Arm Label: Arm 1 Secondary Risk Factor Management; Type: EXPERIMENTAL; Interventions: Behavioral: Physician stroke guideline adherence, Behavioral: Stroke Self Management | Arm Label: Attention Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Attention Control Group | Intervention Type: BEHAVIORAL; Name: Physician stroke guideline adherence; Assigned to Arm(s): Arm 1 Secondary Risk Factor Management | Intervention Type: BEHAVIORAL; Name: Stroke Self Management; Assigned to Arm(s): Arm 1 Secondary Risk Factor Management | Intervention Type: OTHER; Name: Attention Control Group; Assigned to Arm(s): Attention Control Group
C: Arm Label: optimised follow-up; Type: OTHER; Interventions: Other: optimised follow-up | Arm Label: typical follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: optimised follow-up; Assigned to Arm(s): optimised follow-up
D: Arm Label: Control - usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Manual; Type: ACTIVE_COMPARATOR; Interventions: Other: 'The Healthy Brain Rehabilitation Manual', Procedure: Usual care | Arm Label: Manual + pedometer, 1; Type: ACTIVE_COMPARATOR; Interventions: Other: 'The Healthy Brain Rehabilitation Manual', Device: Pedometer, Procedure: Usual care, Behavioral: Telephone follow-up | Arm Label: Manual + pedometer, 2; Type: ACTIVE_COMPARATOR; Interventions: Other: 'The Healthy Brain Rehabilitation Manual', Device: Pedometer, Procedure: Usual care, Behavioral: Telephone follow-up | Intervention Type: OTHER; Name: 'The Healthy Brain Rehabilitation Manual'; Assigned to Arm(s): Manual, Manual + pedometer, 1, Manual + pedometer, 2 | Intervention Type: DEVICE; Name: Pedometer; Assigned to Arm(s): Manual + pedometer, 1, Manual + pedometer, 2 | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Manual, Manual + pedometer, 1, Manual + pedometer, 2 | Intervention Type: BEHAVIORAL; Name: Telephone follow-up; Assigned to Arm(s): Manual + pedometer, 1, Manual + pedometer, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Various Oral Hygiene Procedures on the Reduction of Oral Malodor in Periodontally Healthy Patients
Brief Summary: The purpose of the study is to evaluate the effect of various oral hygiene procedures on reduction of oral malodor.


Options:
A: Arm Label: test; Type: EXPERIMENTAL; Interventions: Device: glycine powder air-polishing (Air-Flows)Perio Powder, Device: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Device: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) | Intervention Type: DEVICE; Name: glycine powder air-polishing (Air-Flows)Perio Powder; Assigned to Arm(s): test | Intervention Type: DEVICE; Name: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland); Assigned to Arm(s): control, test
B: Intervention Type: OTHER; Name: Chlorine Dioxide; Assigned to Arm(s): N/A
C: Intervention Type: OTHER; Name: Chlorine Dioxide; Assigned to Arm(s): N/A
D: Arm Label: group 1: drug; Type: EXPERIMENTAL; Interventions: Drug: group 1: drug: chlorine dioxide | Arm Label: group 2: device:; Type: EXPERIMENTAL; Interventions: Device: group 2: device: small tooth brush for tongue cleaning | Intervention Type: DRUG; Name: group 1: drug: chlorine dioxide; Assigned to Arm(s): group 1: drug | Intervention Type: DEVICE; Name: group 2: device: small tooth brush for tongue cleaning; Assigned to Arm(s): group 2: device:

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Creating Health and Safety Communities of Practice for Home Care Workers
Brief Summary: The current project is a safety and health intervention for home care workers conducted within the Oregon Healthy Workforce Center (OHWC), a NIOSH Center of Excellence in Total Worker Health.

The objective of this five-year project is to create sustainable health and safety "communities of practice" within a population of typically isolated home care workers. The intervention is a team-based, peer-led scripted curriculum that integrates health promotion and protection topics, as well as proven elements of social support groups for caregivers. The investigators hypothesize that this intervention will increase measures of experienced community of practice, well-being, and diet, exercise, and safety behaviors, as compared to a usual practices control condition.


Options:
A: Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): N/A
B: Arm Label: 1-800-QUIT-NOW Telephone Hotline; Type: OTHER; Interventions: Other: 1-800-QUIT-NOW Telephone Hotline | Arm Label: Tobacco Tactics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Tactics Web-Based Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Tactics Web-Based Intervention; Assigned to Arm(s): Tobacco Tactics Intervention | Intervention Type: OTHER; Name: 1-800-QUIT-NOW Telephone Hotline; Assigned to Arm(s): 1-800-QUIT-NOW Telephone Hotline
C: Arm Label: multi-component intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Sit-stand workstation only; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Usual practice (seated workstation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sit-stand workstation provision; Assigned to Arm(s): Sit-stand workstation only, multi-component intervention
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: REVITIVE for the Treatment of Patients With Venous Insufficiency
Brief Summary: To investigate the efficacy of an electrical stimulation (using the REVITIVE IX device) in treating patients with venous insufficiency.


Options:
A: Arm Label: REVITIVE IX: actual device; Type: ACTIVE_COMPARATOR; Interventions: Device: REVITIVE IX | Arm Label: REVITIVE IX: sham device; Type: SHAM_COMPARATOR; Interventions: Device: REVITIVE IX | Intervention Type: DEVICE; Name: REVITIVE IX; Assigned to Arm(s): REVITIVE IX: actual device, REVITIVE IX: sham device
B: Arm Label: İnspiratory muscle training group; Type: EXPERIMENTAL; Interventions: Other: exercise therapy | Arm Label: Calf muscle training group; Type: EXPERIMENTAL; Interventions: Other: exercise therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: exercise therapy; Assigned to Arm(s): Calf muscle training group, İnspiratory muscle training group
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Behavioral: 30-minute education session | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 30-minute education session | Intervention Type: DEVICE; Name: Fitbit; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: 30-minute education session; Assigned to Arm(s): Control, Intervention
D: Arm Label: Crenobalneotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Crenobalneotherapy | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Crenobalneotherapy; Assigned to Arm(s): Crenobalneotherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men
Brief Summary: Primary objective

To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: hepatitis A inactivated virus vaccine | Intervention Type: BIOLOGICAL; Name: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: hepatitis A inactivated virus vaccine; Assigned to Arm(s): Havrix Group
B: Arm Label: V503; Type: EXPERIMENTAL; Interventions: Biological: V503 | Arm Label: GARDASIL; Type: ACTIVE_COMPARATOR; Interventions: Biological: GARDASIL | Intervention Type: BIOLOGICAL; Name: V503; Assigned to Arm(s): V503 | Intervention Type: BIOLOGICAL; Name: GARDASIL; Assigned to Arm(s): GARDASIL
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group
D: Arm Label: HPV Vaccine; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PRimary Prevention Of Depression in Offspring of Depressed Parents
Brief Summary: The purpose of this randomised controlled trial is to see whether a group-based psychological intervention for families can reduce the inflated risk of depression in children and adolescents who have at least one parent who suffers from depression (or who has suffered from depressed in the child's lifetime).


Options:
A: Arm Label: 1= Cognitive behavioral prevention of depression program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral prevention program | Arm Label: 2 = Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral prevention program; Assigned to Arm(s): 1= Cognitive behavioral prevention of depression program | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2 = Usual care
B: Arm Label: Intrinsic Motivation; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CATCH-IT Internet Site | Arm Label: Extrinsic Motivation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BA (brief advice) + CATCH-IT Internet site | Intervention Type: BEHAVIORAL; Name: MI + CATCH-IT Internet Site; Assigned to Arm(s): Intrinsic Motivation | Intervention Type: BEHAVIORAL; Name: BA (brief advice) + CATCH-IT Internet site; Assigned to Arm(s): Extrinsic Motivation
C: Intervention Type: BEHAVIORAL; Name: Screening (Behavior); Assigned to Arm(s): N/A
D: Arm Label: Prevention programme; Type: EXPERIMENTAL; Interventions: Behavioral: Prevention programme | Arm Label: Control (treatment as usual); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prevention programme; Assigned to Arm(s): Prevention programme

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Biomechatronic System Using Voluntary Motor Effort (VME)-Driven Neuromuscular Electrical Stimulation (NMES) for Upper Limb Rehabilitation
Brief Summary: The purpose of this study is to investigate the combined training effectiveness of mechanical robot and neuromuscular electrical stimulation on upper limb rehabilitation after stroke.


Options:
A: Arm Label: Ankle-Foot Orthosis (AFO); Type: ACTIVE_COMPARATOR; Interventions: Other: Ankle-Foot Orthosis (AFO) | Arm Label: WalkAide; Type: ACTIVE_COMPARATOR; Interventions: Device: WalkAide | Intervention Type: DEVICE; Name: WalkAide; Assigned to Arm(s): WalkAide | Intervention Type: OTHER; Name: Ankle-Foot Orthosis (AFO); Assigned to Arm(s): Ankle-Foot Orthosis (AFO)
B: Arm Label: Device-assisted rehabilitation; Type: EXPERIMENTAL; Interventions: Device: Electrical Stimulation; Rehabilitation Robot | Intervention Type: DEVICE; Name: Electrical Stimulation; Rehabilitation Robot; Assigned to Arm(s): Device-assisted rehabilitation
C: Arm Label: Ankle-foot orthosis (AFO) Control Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Ankle-foot orthosis | Arm Label: Ness L300 Treatment Group; Type: EXPERIMENTAL; Interventions: Device: Ness L300 | Intervention Type: DEVICE; Name: Ness L300; Assigned to Arm(s): Ness L300 Treatment Group | Intervention Type: DEVICE; Name: Ankle-foot orthosis; Assigned to Arm(s): Ankle-foot orthosis (AFO) Control Group
D: Arm Label: IpsiHand; Type: EXPERIMENTAL; Interventions: Device: IpsiHand Device | Intervention Type: DEVICE; Name: IpsiHand Device; Assigned to Arm(s): IpsiHand

Answer: B